422 related articles for article (PubMed ID: 18057656)
1. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
2. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
3. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
4. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
5. A review of combination regimens for osteoporosis--prevention and treatment.
Miller E; Kalin MF
Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
[TBL] [Abstract][Full Text] [Related]
6. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis.
Garcés C; García LE
Maturitas; 2006 Apr; 54(1):47-54. PubMed ID: 16257150
[TBL] [Abstract][Full Text] [Related]
7. The potential of parathyroid hormone as a therapy for osteoporosis.
Rubin MR; Bilezikian JP
Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
[TBL] [Abstract][Full Text] [Related]
8. Daily and cyclic parathyroid hormone in women receiving alendronate.
Cosman F; Nieves J; Zion M; Woelfert L; Luckey M; Lindsay R
N Engl J Med; 2005 Aug; 353(6):566-75. PubMed ID: 16093465
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of osteoporosis with parathyroid hormone].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
[TBL] [Abstract][Full Text] [Related]
11. [Regulation of bone mineralization by parathyroid hormone].
Shimizu M; Tamura T
Clin Calcium; 2004 Jun; 14(6):70-5. PubMed ID: 15577058
[TBL] [Abstract][Full Text] [Related]
12. [New, pioneering PTH treatment of postmenopausal osteoporosis. Quick effect on bone density and bone formation].
Törring O
Lakartidningen; 2001 Oct; 98(42):4552-3. PubMed ID: 11715225
[No Abstract] [Full Text] [Related]
13. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
Sellmeyer DE; Black DM; Palermo L; Greenspan S; Ensrud K; Bilezikian J; Rosen CJ
Osteoporos Int; 2007 Jul; 18(7):973-9. PubMed ID: 17333451
[TBL] [Abstract][Full Text] [Related]
14. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
15. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
Compston JE
Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone treatment for osteoporosis.
Cosman F
Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):495-501. PubMed ID: 18971677
[TBL] [Abstract][Full Text] [Related]
17. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
Nemeth EF
IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
19. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
[TBL] [Abstract][Full Text] [Related]
20. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
Park JH; Park KH; Cho S; Choi YS; Seo SK; Lee BS; Park HS
Menopause; 2013 Jul; 20(7):747-53. PubMed ID: 23511701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
